Crocetin as a Neuroprotective Agent: Targeting Western Diet-Induced Cognitive Dysfunction Through Antioxidant,...

Area of Science:

• Neuroscience
• Nutritional Science
• Pharmacology

Background:

• Western diets high in fat, sugar, and processed foods induce cognitive dysfunction via neuroinflammation, oxidative stress, and gut dysbiosis.
• Blood-brain barrier (BBB) disruption and synaptic dysfunction are key consequences of these dietary patterns.
• Crocetin, a natural apocarotenoid, demonstrates potential neuroprotective properties.

Purpose of the Study:

• To critically assess the mechanistic links between crocetin and the amelioration of Western diet-induced cognitive decline.
• To distinguish well-supported findings from speculative associations in preclinical and human evidence.
• To discuss the therapeutic prospects of crocetin, considering its limitations and potential advanced formulations.

Main Methods:

• Review of preclinical studies on crocetin's effects on neuroinflammation, oxidative stress, and gut microbiota.
• Analysis of early clinical evidence regarding crocetin's impact on cognitive functions and cerebral blood flow.
• Evaluation of crocetin's pharmacokinetic properties, bioavailability challenges, and potential advanced delivery systems.

Main Results:

• Preclinical data strongly support crocetin's efficacy in mitigating Western diet-induced neurodegeneration.
• Early human trials indicate improvements in memory, executive function, and cerebral blood flow with crocetin.
• Crocetin exhibits neuroprotective mechanisms including antioxidant activity, anti-inflammatory effects, enhanced mitochondrial function, and gut microbiota modulation.

Conclusions:

• Crocetin demonstrates significant potential as a neuroprotective agent against Western diet-induced cognitive decline.
• Limitations in bioavailability and metabolism necessitate the development of advanced formulations for clinical translation.
• Future research should focus on large-scale trials and pharmacokinetic optimization to establish crocetin's clinical viability.